#United States #Amgen #Thousand Oaks #Sjögren's Disease #Dazodalibep

Amgen's Significant Progress in Sjögren's Disease Treatment

Amgen recently announced groundbreaking findings from its Phase 3 clinical trial, OASIZ-301, for the treatment of Sjögren's Disease using its investigational drug, Dazodalibep. This trial stands out as the only global Phase 3 study that presents clinically meaningful improvements in patients' systemic disease activity and symptoms, marking a significant leap in the treatment of a disease that currently lacks FDA-approved therapies.

The results, revealed during a late-breaking session at the American College of Rheumatology (ACR) Convergence 2026, are based on a robust methodology that involved a randomized, double-blind, placebo-controlled study. The primary endpoint focused on changes in the European Alliance of Associations for Rheumatology Sjögren's Syndrome Disease Activity Index (ESSDAI) after 48 weeks of treatment.

In this trial, patients exhibited a mean baseline ESSDAI score of 10.2, indicating moderate to severe systemic disease activity. Remarkably, both dosing regimens of Dazodalibep—1,500 mg every four weeks and 3,000 mg every 12 weeks—surpassed the primary effectiveness threshold. The 1,500 mg dosage demonstrated a least-squares mean reduction of 5.6 points from the baseline, significantly eclipsing the placebo reduction of 3.8 points, with an adjusted p-value of less than 0.001. Similarly, the 3,000 mg dosage exhibited a decrease of 5.2 points, showcasing its potency in altering disease progression.

One of the most significant aspects of the findings was the early onset of treatment effects, with improvements observable as soon as Week 4 and sustained through the 48-week mark. This rapid response is crucial for patients who suffer from debilitating symptoms associated with Sjögren's Disease, including persistent dryness, fatigue, and joint pain. At the 48-week assessment, the 1,500 mg treatment also indicated a significant reduction in patient-reported dryness—an important symptom of this condition—with dry mouth and eye assessments revealing statistically meaningful improvements when compared to placebo (p<0.001).

Dr. Jay Bradner, Amgen's executive vice president of Research and Development, underscored the importance of these results, stating that they bolster Dazodalibep's position as a potential first-in-class treatment option. He highlighted the need to target the CD40L-mediated immune signaling pathway in developing effective therapies for Sjögren's Disease.

The trial’s detailed analysis revealed that a larger percentage of patients receiving Dazodalibep achieved clinically significant reductions on the ESSDAI scale. Additionally, improvements were noted in patient-reported outcomes concerning fatigue and oral dryness, reinforcing the treatment's dual effectiveness on both systemic and symptomatic fronts.

In response to the study, Janet Church, CEO of the Sjögren's Foundation, expressed optimism, stating that the need for new treatment options is pressing due to the widespread and debilitating nature of Sjögren's Disease. She emphasized the research momentum and the foundation's hope that these findings would lead to viable treatment alternatives that diversify the options available to patients.

The safety profile of Dazodalibep was also evaluated, revealing that the most common adverse events included nasopharyngitis, urinary tract infections, and mild to moderate infusion-related reactions. Overall, the balance of serious adverse events was consistent across treatment and placebo groups, indicating that Dazodalibep not only shows promise in efficacy but is also manageable in terms of safety.

Overall, Amgen's OASIZ-301 trial results represent a significant academic and clinical advancement for the treatment of Sjögren's Disease. As the company gears up to conduct broader Phase 3 studies, the implications of these findings hold potential to reshape the therapeutic landscape for the millions suffering from this under-recognized autoimmune ailment. The ongoing commitment to research and development could soon yield new hope for patients who have long awaited effective interventions for their complex health challenges.